Metex (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, halting the production of tetrahydrofolate needed for DNA, RNA and protein synthesis. By limiting nucleic acid formation, it suppresses the proliferation of rapidly dividing cells such as immune‑mediated inflammatory cells and malignant tumor cells, providing both anti‑inflammatory and anticancer effects.

The dosage of Metex is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Physicians determine the appropriate amount, frequency, and route of administration, and patients should follow the prescriber’s written instructions without deviation.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and miscarriage. It is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and harm the infant. Effective contraception is required for women of childbearing potential during treatment.

To request Metex, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and assistance with import documentation.

Methotrexate is a cornerstone antimetabolite and is often compared with agents such as leflunomide for rheumatoid arthritis or azathioprine for immunosuppression. Compared with biologic therapies, methotrexate is less expensive and administered orally or by injection, but it may require more laboratory monitoring for hepatic and hematologic toxicity.

Metex should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from direct light and moisture, and avoid freezing. If the product is supplied as a refrigerated preparation, follow the specific cold‑chain instructions provided by the supplier.

Metex is supplied as a sterile injectable solution and can be given by intramuscular, intravenous, or subcutaneous injection, depending on the clinical indication and prescriber preference. Administration is performed by a qualified healthcare professional in a controlled setting, following aseptic technique and appropriate dosing guidelines.

The most critical risks include severe liver toxicity, pulmonary fibrosis, life‑threatening infections due to immunosuppression, bone‑marrow failure leading to aplastic anemia, and renal failure. Patients should be monitored regularly for liver enzymes, pulmonary symptoms, blood counts, and renal function to detect these complications early.

Metex is contraindicated in pregnant women, individuals with severe hepatic impairment, uncontrolled renal dysfunction, active infections, and known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with pre‑existing blood dyscrasias or pulmonary disease.